Landscapes / Targets
pan-KRAS
7 drugs act on pan-KRAS, in 9 active trials · Any stage · updated 20 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs7
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | 31 Dec 2026Phase 1/2 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Advanced Solid Tumors and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Oct 2028Phase 1/2 trial completes | |||
| Next date | 30 Oct 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Sep 2029Phase 1/2 trial completes | |||
| Next date | Sep 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Non-Small Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Aug 2027Phase 1 trial completes | |||
| Next date | Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, NSCLC and 12 more | ||||
| Open drug page | |||||
— |
Eli Lilly · Public LLY |
Phase 1 | Jan 2030Phase 1 trial completes | ||
| Next date | Jan 2030 · Phase 1 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
— |
Pfizer · Public PFE |
Phase 1 | — | ||
| Also tested for | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 7 of 7 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · openFDA updated 20 Nov 2026